The maker of the antidepressant Cymbalta said it expects adjusted earnings to range between $3.10 and $3.20 per share on between $20.3 billion and $20.8 billion in revenue in the new year, as it continues to recover from the loss of patents protecting several key products from cheaper generic drugs. That would represent as much as 17 percent growth from its forecast for 2014 earnings of between $2.72 and $2.80 per share.